Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T1D Plus trial of verapamil alone versus verapamil plus immunotherapy in newly diagnosed type 1 diabetes
ISRCTN45965456Phase 2Terminated
- Sponsor
- Cardiff University
- Start
- Jun 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial in diabetes mellitus type 1 (T1D) comparing Verapamil alone, Verapamil plus ATG and Verapamil plus golimumab (3 arms). Primary endpoint: Stimulated C-peptide AUC at 12 months. Started Jun 2024; status: terminated.
02
Drugs
verapamilantithymocyte globulin rabbitgolimumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on ISRCTN45965456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN45965456.